Urogen Pharma (NASDAQ:URGN) Shares Down 5.3% - Should You Sell?

Urogen Pharma (NASDAQ:URGN - Get Free Report)'s stock price traded down 5.3% during mid-day trading on Tuesday . The company traded as low as $13.42 and last traded at $13.55. 601,578 shares were traded during trading, a decline of 42% from the average session volume of 1,041,037 shares. The stock had previously closed at $14.30.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Scotiabank reaffirmed an "outperform" rating on shares of Urogen Pharma in a report on Friday, June 13th. D. Boral Capital reaffirmed a "buy" rating and issued a $25.00 target price on shares of Urogen Pharma in a report on Thursday, June 12th. HC Wainwright upgraded Urogen Pharma from a "neutral" rating to a "buy" rating and set a $50.00 price target on the stock in a research note on Monday, June 16th. Guggenheim reaffirmed a "buy" rating and issued a $30.00 target price (up previously from $15.00) on shares of Urogen Pharma in a research note on Friday, June 13th. Finally, Oppenheimer set a $31.00 price target on shares of Urogen Pharma and gave the stock a "buy" rating in a research report on Friday, June 13th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $32.86.

Urogen Pharma Price Performance

The company has a debt-to-equity ratio of 4.77, a current ratio of 5.65 and a quick ratio of 5.47. The stock has a market capitalization of $632.63 million, a price-to-earnings ratio of -4.31 and a beta of 0.40. The company has a 50-day simple moving average of $9.12 and a two-hundred day simple moving average of $10.14.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.09). The firm had revenue of $20.25 million during the quarter, compared to analyst estimates of $22.71 million. Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 150.68%. On average, equities research analysts predict that Urogen Pharma will post -3.12 earnings per share for the current year.

Insider Activity

In related news, insider Mark Schoenberg sold 5,162 shares of the stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $7.37, for a total value of $38,043.94. Following the completion of the transaction, the insider now directly owns 153,378 shares of the company's stock, valued at $1,130,395.86. This represents a 3.26% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 5.10% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Rhumbline Advisers grew its position in Urogen Pharma by 2.8% in the 4th quarter. Rhumbline Advisers now owns 51,270 shares of the company's stock valued at $546,000 after buying an additional 1,402 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Urogen Pharma by 7.3% in the 4th quarter. Bank of New York Mellon Corp now owns 93,997 shares of the company's stock worth $1,001,000 after acquiring an additional 6,430 shares during the period. ARK Investment Management LLC boosted its holdings in shares of Urogen Pharma by 15.2% in the fourth quarter. ARK Investment Management LLC now owns 140,148 shares of the company's stock valued at $1,493,000 after acquiring an additional 18,514 shares in the last quarter. Oppenheimer & Co. Inc. acquired a new position in shares of Urogen Pharma during the fourth quarter valued at approximately $126,000. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Urogen Pharma by 3.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 93,517 shares of the company's stock valued at $996,000 after acquiring an additional 3,024 shares during the period. 91.29% of the stock is owned by institutional investors and hedge funds.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.